Press Release

For immediate release                                                                                    

12 September 2017

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Extraordinary General Meeting results

The Board of MedicX Fund Limited (LSE: MXF), is pleased to announce that at the Extraordinary General Meeting of its Shareholders held at 4.30 p.m. today, the special resolution proposing that the Company becomes resident in the United Kingdom for tax purposes and enters the UK REIT regime, was duly passed.  The details of the resolution were as follows: 

It was resolved that the Proposals (as defined in the Company's circular to shareholders dated 18 August 2017) be approved and that with effect from 00.01a.m. on 29 September 2017, the new articles of incorporation of the Company produced to the meeting containing amendments required for the purposes of the Company's entry into the UK REIT regime be adopted.

In Favour - 178,223,806 (99.92%)

Against - 138,078 (0.08%)

Withheld - Nil

David Staples, Chairman of MedicX Fund, commented:

"We are delighted that the Fund's shareholders have strongly supported the Company's proposal to convert to a UK REIT. Entry into the UK REIT regime will benefit our shareholders by exempting future profits from the Company's Qualifying Property Rental Business from UK corporation tax. REIT status is the next step in the Company's growth journey which will also potentially widen the appeal to new investors."

Notes:

·      The votes "in favour" of the resolution are calculated as the aggregate of proxy instructions voting "in favour" of the resolution and the votes at the Chairman's discretion.

·      A vote "withheld" is not a vote in law and is not calculated in the proportion of the votes "in favour" or "against" the resolution.

·      The total number of voting rights as at the proxy deadline was 428,530,249.

End

For further information please contact:

MedicX Fund                                                                              +44 (0) 1481 723 450

David Staples, Chairman                                                            

Octopus Healthcare Group                                                          +44 (0) 20 3142 4820

Mike Adams, Chief Executive Officer

Canaccord Genuity

Andrew Zychowski/Helen Goldsmith                                             +44 (0) 20 7523 8000

Buchanan                                                                                  +44 (0) 20 7466 5000

Charles Ryland/Vicky Hayns

Information on MedicX Fund Limited

MedicX Fund Limited (the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 156 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1.1 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £7 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 100,000 customers.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com.  Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25.